Pulmonary administration of immunoglobulin single variable domains and constructs thereof

US9725522B2 · kind B2 · utility

Assignee

• Ablynx N.V. · BE

Inventors

• Marie-Paule Lucienne Armanda Bouche · Gentbrugge, BE
• Peter Vanlandschoot · Bellem, BE
• Erwin Sablon · Mechelen, BE
• Erik Depla · Laarne, BE
• Stefan De Buck · Basel, CH
• Xavier Saelens · Ieper, BE
• Bert Schepens · Evergem, BE
• Karen Silence · Overijse, BE
• Mark Vaeck · Zemst, BE
• Paul M. P. Van Bergen En Henegouwen · Utrecht, NL
• Hans De Haard · Oudelande, NL

Key dates

• Filing date: Mar 8, 2016
• Grant date: Aug 8, 2017
• Expiry date: Mar 8, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.